1. The Rising Cost of Healthcare and Potential Impact of Biosimilars

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in full form in a peer-reviewed journal.

3. Psoriasis Prevalence is Increasing

4. Initial History of Monoclonal Antibody Development

5. Psoriasis: More Patients to Treat -- More Treatments for Patients -- More costs

6. Differences Between Biologics and Small Molecules

7. Challenges With Development of Biosimilar

8. What Could We Gain from Marketed Biosimilars?

9. Impact of the Biosimilar Filgrastim

10. The Therapeutic Relationship Between HCP and Patient is Important

11. Switching Patients From Originator to Biosimilar

12. Initiatives to Influence Uptake of Biosimilars

13. NOR-SWITCH Experience

14. Overview of Biosimilar Use Across Europe

15. UK HSCIC Data and Potential Savings From Just 1 Class of Drugs

16. UK HSCIC Data and Potential Savings From Just 1 Class of Drugs (cont)

17. Long-Term Data on Switching

18. Meta-Analyses on Switching From Reference Medicines to Biosimilars

19. Biosimilars and Extrapolation

20. National Clinical Audit of Biologic Therapies for IBD in the UK

21. Pharmacovigilance

22. Concluding Remarks

23. Abbreviations